Empowering Researchers in Cancer and Precision Medicine
We support researchers in understanding the molecular individuality of cancer.
Every tumor is unique — shaped by evolutionary processes that allow it to evade apoptosis, immune surveillance, or therapeutic intervention. These adaptive mechanisms are driven by genetic mutations and epigenetic modifications (e.g., DNA methylation) and reflected in altered gene expression, protein activity, and regulatory RNAs such as small RNAs.
Our cutting-edge technologies help scientists decode the tumor genome, epigenome, and transcriptome at the highest resolution. Through high-performance bioinformatics, we compare tumor-specific data with large molecular databases to reveal actionable pathways and potential therapeutic targets.
By providing detailed molecular insights, we help researchers identify drugs that are most likely to disrupt the survival mechanisms of specific tumors.
Nucleic Acid-Based Analyses from Liquid Biopsies: Exosomal Cargo and Other Molecular Markers
We assist researchers in exploring circulating nucleic acids from liquid biopsies, including exosomal DNA and RNA from blood or urine.
Our proprietary TrueQuant® technology is essential for these analyses: since cfDNA and RNA molecules in biofluids are often scarce, they must be amplified before sequencing — a process that traditionally introduces strong biases.
By using Unique Molecular Identifiers (UMIs), TrueQuant® eliminates amplification bias, enabling highly accurate and quantitative sequencing of low-input samples.
This precision makes our technology ideal for liquid biopsy-based biomarker discovery and early detection research.
Find more details on our Liquid Biopsy Solutions
Nucleic Acid-Based Analyses from Liquid Biopsies: Exosomal Cargo and Other Molecular Markers
By applying highly sensitive eloborated methods, we obtain nucleotide-based -signatures in the blood or urine, including from exosomes. For this, our TrueQuant method is of vital importance: becasue blood-based nucleotide markers are usually only present in very small amounts, they need to be amplified in order to analyze them via NGS. This amplification usually leads to a strong bias and falsified results. Our TrueQuant method allows do eliminate the bias and hence leads to a much higher accuracy. Find more about liquid biopsies here.
Therefore, we are the perfect partner for biomarker detection especially from low amounts of starting matierial.
Drug effects / Pharmacokinetics
our high-resolution transcriptome and methylation analyses are ideally suited for the analyses of drug effects, to monitor changes in gene expression and/or methylation. MACE-Seq is a highly senstive RNA-Sequencing method for the partially degraded RNA from FFPE-slides and thanks to our TrueQuant method for highly accurate results, samples can be analyzed in a highly parallelized fashion at low costs and high reliability.
Gene Expression AND Mutations
GenXPro supports multidisciplinary research teams and molecular tumor boards by integrating gene expression and mutation data into unified, interpretable results.
While conventional precision-oncology studies focus primarily on somatic mutations, our approach also reveals functionally active genes and pathways that drive tumor persistence and therapy resistance.
By combining functional (transcriptomic) and genetic (mutational) information, we help researchers and clinicians define knowledge-based, targeted treatment strategies for improved patient outcomes.
Biomarker Discovery
We help researchers discover and validate biomarkers from DNA, RNA, small RNA, or methylation patterns in tissues, circulating nucleic acids, cells, and exosomes.
Our patented, high-resolution sequencing technologies provide unmatched accuracy, even from minute input amounts, making them ideal for translational studies, early diagnostics research, and non-model organism projects.
Disclaimer:
All analyses are for research use only and not yet approved for clinical diagnostics.